



MENA Oncology Conference

22nd & 23rd October 2010
Cairo, Egypt

KEY SPEAKERS AND PANELISTS

Dr Ibtihal Fadhil
World Health Organization (WHO)
the Regional Office for The Eastern Mediterranean EMRO, Regional Adviser

Prof Nada Alwan
Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

Dr Hussein Khaled
Cairo University, Egypt
Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Dr Heba Sweed, **Global Initiative for Breast Cancer Awareness, Egypt**
Country Program Manager

Dr Raghib Ali
INDOX Cancer Research Network, UK
Director

Dr Andy Smith
Hologic Inc, USA, Senior Director

Dr Ashraf Selim, **Cairo University, Egypt**
Head Of Women's Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of **Egyptian Society of Women's Imaging & Health Care (ESWIH)**

Dr Amal Samy Ibrahim
National Cancer Institute, Egypt
Professor of Epidemiology and Director of the National Cancer Registry of Egypt

Dr Rabab Gaafar
NCI, Cairo University
Prof and Head of Medical Oncology Dept & National Representative of **ESMO in Egypt and Africa**

Dr Omalkhair Abulkhair
King Abdul Aziz Medical city, KSA
Section Head & Consultant, Dept of Oncology

Dr Mohamed Shaalan
Breast Cancer Foundation of Egypt
Director

Dr Shaheenah Dawood
Dubai Hospital, UAE
Head of Medical Oncology

Dr Norran H. Said, **Cairo University, Egypt**, Breast Radiologist and **Egyptian Society of Women's Imaging & Health Care**, Treasurer

Dr Sanjay Raj Jain
TAWAM HOSPITAL, UAE, Department of Haematology and Oncology, Chairman

Dr Aly Abdel Razeq
Gulf International Cancer Center, UAE
Executive Director

Dr Sidi Mohamed Taher Alaoui
Lalla Salma Association, Morocco
President of Scientific Committee

Dr Anthony B. Miller
Dalla Lana School of Public Health, University of Toronto, Canada
Associate Director, Research

Dr Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland
Director, Experimental Oncology

Dr Hatem Azim, **Jules Bordet Institute, Belgium**, Research Fellow

Dr Münir Kinay
Dokuz Eylul University, Turkey
Head of Department of Radiation Oncology

Prof Dr Alaa Kandil
Alexandria School of Medicine, Egypt
Professor of Clinical Oncology

Dr Sayed A Marei, **Cairo University, Egypt**, Professor of General Surgery and Head of the Breast Surgery Clinic

YOUR PRESTIGIOUS ADVISORY PANEL

Chairman:
Dr Anthony B. Miller
Dalla Lana School of Public Health, University of Toronto, Canada
Associate Director, Research

Dr David Kerr, **Sidra Medical and Research Center, Qatar**
Chief Research Adviser

Dr Salwa Boulos
Galla Hospital, Egypt
Breast Radiologist

Dr Hussein Khaled
Cairo University, Egypt
Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Dr Ashraf Selim
Cairo University, Egypt
Head Of Women's Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of **Egyptian Society of Women's Imaging & Health Care (ESWIH)**

Dr Suad Bint Mohamed Bin Amer
King Faisal Specialist Hospital and Research Centre KSA
Head of Breast Cancer Research Unit
Zahra Breast Cancer Association, KSA
Founder and Co-Chairman

Dr Carlo V. Catapano
Oncology Institute of Southern Switzerland, Switzerland, Director,
Experimental Oncology

Dr Raul Ribeiro
St Jude Children research hospital, USA,
Director, International Outreach Program and Leukemia / Lymphoma Division

Dr Aida Hussein, **Federal Ministry of Health, Sudan**, Coordinator of the Breast Cancer Control Programme

Dr Ahmad Al Khateib
King Hussein Cancer Center, Jordan
Director of Training

MEMBERS

EVENT OVERVIEW

Cancer is a major public health problem that affects every country in the MENA (Middle East & North Africa) region regardless of economic and social situation and this Conference will focus mainly on the Breast Cancer as it is the most common type of cancer in this region.

This conference will also include new information, consolidated knowledge, and conversations on controversial issues regarding Prevention & Risk of Breast cancer, Imaging & Screening, new approaches in targeted therapies, and more.

MENA Oncology Conference will be a great opportunity for governmental and non-governmental cancer control officials; for physicians, researchers and health professionals; and also for patients, advocates, volunteers and others interested in cancer control, from all over the world, to get together and exchange views on how to deal with cancer.

WHO WILL ATTEND?

- Governmental and non-governmental cancer control officials
- Medical, surgical, and radiation oncologists, haematologists and pathologists interested in the treatment of patients with Breast cancer
- Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of Breast cancer are also invited to attend.

Bronze Sponsor



Supporting associations:



Strategic Partner: Media Partners:





Day 1 | 22nd October 2010

8:00 Registration and Coffee

9:00 Opening remarks from the chair

Co-Chairman: Dr Andy Smith, Hologic Inc, USA
Senior Director

▶ Regional Perspective on Breast Cancer

9:10 Breast Cancer in Eastern Mediterranean Region & WHO strategic interventions

- Current Situation of Breast Cancer in the MENA region.
- WHO Strategic intervention to control cancer

Dr Ibtihal Fadhil, World Health Organization (WHO), The Regional Office for The Eastern Mediterranean EMRO, Regional Adviser

9:30 Introducing a Comprehensive Information System on Breast Cancer Control in the Eastern Mediterranean Region

- Apart from being the commonest cancer among women in countries within the Eastern Mediterranean Regions (EMR), there are other factors that justify increasing efforts for breast cancer control. These include younger ages at presentation, late stages at first diagnosis and the prevalence of more aggressive tumour behavioural forms.
- High mortality/incidence ratio is a usual finding in those countries. Most of the national cancer registries in the EMR lack data regarding age-specific incidence rates, stage of disease at presentation and survival rates.
- A comprehensive database breast cancer information system was designed under supervision of IARC (International Agency for Research on Cancer) to compare the demographic characteristics, clinicopathological presentations and treatment outcomes of breast cancer patients within selected countries in the Middle East including Iraq, Jordan, Lebanon and Egypt

Prof. Nada Alwan, Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

9:50 The Challenges facing national cancer control plans (Egypt Case)

- Causes of The Growing Cancer burden
- Challenges facing the Cancer control plans
- Local strategies to overcome these Challenges

Dr Amal Samy Ibrahim
National Cancer Institute, Egypt
Professor of Epidemiology

10:30 Morning Coffee and Networking

11:00 The Global Initiative for Breast Cancer Awareness in Egypt, Relation between awareness and early detection of breast cancer

Dr. Heba Sweed, Global Initiative for Breast Cancer Awareness, Egypt, Country Program Manager

▶ Controversies in Breast cancer: Adjuvant and Neoadjuvant Therapy

11:40 Optimizing Endocrine Therapy for Indolent Breast cancer

- In Premenopausal women
- In Postmenopausal
- Preoperative Endocrine therapy

Dr Hussein Khaled

Cairo University, Egypt

Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

12:20 Controversies in Neoadjuvant Therapy

- Radiation after Breast Conserving surgery
- Impact of systemic Therapy
- Postmastectomy radiation in 1-3 positive nodes

Dr Rabab Gaafar, NCI, Cairo University, Prof and Head of Medical Oncology Dept & National Representative of **ESMO** in Egypt and Africa

Dr .Münir Kinay, Dokuz Eylul University
Head of Department of Radiation Oncology

13:00 Friday's Prayer and Lunch

▶ Early detection and Screening of Breast cancer

14:30 The Moroccan (Lalla Salma) program in early detection and screening for Breast Cancer

- Primary health care system: screening
- Secondary health care system: diagnosis
- Tertiary health care system: treatment

Dr Sidi Mohamed Taher Alaoui
Lalla Salma Association, Morocco
President of scientific Committee

15:10 Screening for breast cancer - different approaches

- Effects of mammography screening - under different screening schedules:
- Estimates of potential benefits and harms
- Evidence on other screening modalities, CBE and BSE

Dr Anthony B. Miller, Dalla Lana School of Public Health, University of Toronto, Canada
Associate Director, Research

15:50 Afternoon tea and networking

16:20 Molecular Imaging of Breast Cancer using Positron Emission Tomography PET with Breast Computed Tomography CT for Breast Cancer

- Initial Staging of Breast Cancer.
- Post-operative Assessment.
- Evaluate Response to Chemotherapy.

Dr Aly Abdel Razek, Gulf International Cancer Center, UAE, Executive Director

17:00 Magnetic Resonance Imaging MRI of the Breast, when and why?

Magnetic Resonance Imaging (MRI) is a noninvasive procedure, which represents the most sensitive modality for the detection of invasive breast cancer in high risk patients. It is a powerful tool in diagnosing multifocality, or multicentricity, as well as contralateral malignant foci. It can also help assess for residual invasive cancer in patients who have undergone lumpectomy with positive margins at pathology. In assessment of the post operative breast, it has proved reliability in differentiating scar tissue from recurrence, and has proved to be the gold standard in evaluation of silicone implant integrity. However, It is a problem solving tool and should not replace standard screening and diagnostic procedures.

Dr Norran H. Said, Cairo University, Egypt
Breast Radiologist and, **Egyptian Society of Women's Imaging & Health Care**, Treasurer

17:40 Networking Reception and close of Day 1



Day 2 | 23rd October 2010

8:00 Registration and Coffee

9:00 Opening remarks from the chair

Co-Chairman: Dr Andy Smith, Hologic Inc, USA
Senior Director

▶ New Approaches in Targeted Therapy for Breast

9:10 Target-based therapies in breast cancer: Current status and future perspectives

- Identification of molecular alterations in key proteins involved in breast cancer cell proliferation and survival resulted in the development of a new treatment strategy with target-based agents
- The anti-ErbB-2 monoclonal antibody (mAb) trastuzumab and the dual epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor lapatinib are effective in patients with breast cancer that overexpresses ErbB-2.
- The anti-vascular endothelial growth factor-A mAb bevacizumab is approved in combination with taxanes for treatment of unselected patients with metastatic breast cancer.

Dr Shaheenah Dawood, Dubai Hospital, UAE
Head of Medical Oncology

9:50 Interactive Panel Discussion: Promising new agents in Breast Cancer Treatment

- New promising targeted agents in treating Breast Cancer.
- Local Situation in the MENA region.
- How to use these agents
- What is the economic burden
- Guidelines for their use

Prof Dr Alaa Kandil, Alexandria School of Medicine, Egypt, Professor of Clinical Oncology

10:30 Morning Coffee and Networking

▶ Breast Cancer Challenges

11:00 Update and change in the treatment of Triple Negative Breast Cancer

- Challenges of Triple-negative breast cancer (TNBC) treatment.
- Evaluation of DNA-damaging chemotherapy drugs
- Defining the optimal chemotherapy regimen and most effective targeted therapeutic strategy for TNBC.

Dr Omalkhair Abulkhair, King Abdul Aziz Medical city, KSA, Section head & consultant, Dept of Oncology

11:40 Evolving Issues in Inflammatory Breast Cancer

- Epidemiology and Pathology of Inflammatory Breast Cancer
- Biologic underpinnings and radiologic advances
- Treatment modalities for inflammatory Breast Cancer

12:20 Luncheon

13:50 Motherhood in breast cancer survivors: Dream or a reality?

- Effect of systemic anti-cancer therapy on ovarian function
- Feasibility and safety of pregnancy in breast cancer survivors
- Feasibility and safety of breastfeeding in breast cancer survivor
- Methods to preserve fertility, clinical and ethical perspectives

Dr Hatem Azim, Jules Bordet Institute, Belgium
Research fellow

14:30 Establishing a Clinical Research Network across the MENA region

- Clinical research is a critical tool in the fight against cancer as it does not only help to identify the best treatment for individual cancer patients, but also helps governments and agencies develop appropriate plans and long-term strategies for cancer control and prevention.

- The MENA region has well-trained physicians, scientists and well-equipped hospitals in but very limited experience in clinical research. A cooperative group that facilitates collaborative research through providing a platform of action and expertise is needed.
- A Cancer Research Network will therefore be established across the MENA region which will conduct research, training, education, and facilitate collaboration, thereby becoming a regional leader and a major global contributor to oncology research.

Dr Raghieb Ali, INDOX Cancer Research Network, UK, Director

15:10 Interactive Panel Discussion: Are we over treating small screening detected Breast Cancers?

- Earlier diagnosis creates a new situation in which both the diagnostic and the therapeutic team members encounter previously uncommon situations.
- Guidelines for the treatment of small non palpable breast cancers should not be based on trial results obtained from palpable, clinically diagnosed cancers.
- Using the established methods for treating mammographically detected palpable cancers, non-palpable lesions carry a considerable risk of over treatment, because the histologic prognostic parameters do not reliably predict the outcome of 1-14 mm invasive breast cancers

Moderator: Dr Ashraf Selim, Cairo University, Egypt

Head Of Women's Imaging Unit, Consultant of Egyptian National Breast Screening Program & President of **Egyptian Society of Women's Imaging & Health Care (ESWIH)**

Panellists: Dr Mohamed Shaalan, Breast Cancer Foundation of Egypt, Director

Dr Sayed A Marei, Cairo University, Egypt, Professor of General Surgery and Head of the Breast Surgery Clinic

15:50 Afternoon Tea and Networking

▶ Cancer Stem Cells and Breast Cancer Metastasis

16:20 Therapeutic strategies to target cancer stem cells and metastasis

New concepts are challenging our views of critical aspects of tumor biology. Recent research has highlighted the importance of tumor heterogeneity and tumor-initiating cells with stem cell-like properties in tumor initiation and progression. Multiple genetic and epigenetic factors control normal and cancer stem cell biology and are at play in the metastatic cascade. As the pathways involved in these processes are progressively unraveled, new therapeutic targets and strategies will become available for devising more effective treatments for cancer. Although we are still at the early stages of translating these new findings into clinical applications, the initial results are encouraging. We will review the most recent findings on the critical pathways and therapeutic strategies under development.

Dr Carlo V. Catapano, Oncology Institute of Southern Switzerland, Switzerland, Director, Experimental Oncology

17:00 Mechanism of Breast Cancer Metastasis

- The multi-step metastatic cascade
- The importance of tumor heterogeneity, tumor propagating cells and microenvironment

Dr. Sanjay Raj Jain, TAWAM HOSPITAL, UAE

Department of Haematology and Oncology, Chairman

▶ Management of Metastatic disease

17:40 Bone Metastasis of Breast Cancer

- The microenvironment of breast cancer metastasis to bone
- Management strategies
- Current endocrine therapies for the prevention and treatment of metastatic breast cancer

18:20 Closing Remarks from the Chair

I would like to thank everyone who has helped with the research and organization of this event, especially the advisors for their support and commitment.

Doaa Said, doaa.said@fleminggulf.com



Meet Our Prestigious Speaker Panel

Dr Ibtihal Fadhil, World Health Organization (WHO)

The Regional Office for The Eastern Mediterranean EMRO, Regional Adviser

Dr Ibtihal Fadhil is Regional Adviser for Non communicable Diseases at Eastern Mediterranean Regional Office since June 2008. Dr Fadhil graduated in Medicine from Basra College of Medicine. She obtained her post graduate qualifications (MSc, PhD , Diploma) in United Kingdom, London School of Hygiene and Tropical Medicine, in 1983,1987 and in 2003 a NZREX clinical examination at the New Zealand Medical Council, Auckland, New Zealand. Prior to joining WHO, Dr Fadhil held several positions in clinical and academic medicine in different countries. In Iraq, during the period (1978-1991) Dr Fadhil worked as a research fellow and an assistant professor at University of Basra. During this period she worked with WHO as project manager in Southern Iraq. From the period (1991-1995) Dr. Fadhil appointed as Assistant Professor, Faculty of Medicine, University of Jordan, Amman, Jordan. In 1995 Dr. Fadhil moved to New Zealand and appointed as Leader for the Post graduate programs, Health Studies Department, Manukau Institute of Technology, Auckland, New Zealand,(1995- 2002). During this period joined EMRO as Short-term professional in NCD Unit. From the period 2003-2005 working with Primary Health Care Department, BDF Hospital, in Bahrain, and assistant professor, Department of Family and Community Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Bahrain and from 2005 to 2008 as a Consultant Epidemiologist, Directorate of Public Health, Ministry of Health, Bahrain. Dr Fadhil holds several committee membership and services and she is the author of many publications in different topics and fields of expertise which were published in many medical association journals.

Dr Anthony B. Miller, Dalla Lana School of Public Health, University of Toronto, Canada, Associate Director, Research

Professor Emeritus and Associate Director, Research, Dalla Lana School of Public Health, University of Toronto. He is a consultant to the Division of Cancer Prevention US National Cancer Institute and to the World Health Organization, is Co-Chair of the Cancer Risk Management Steering Committee and a member of the Action Council, Canadian Partnership against Cancer. He qualified in Medicine in 1955, was a member of the scientific staff of the UK Medical Research Council, 1962-71, Director of the Epidemiology Unit of the National Cancer Institute of Canada 1971-86, Chair of the Department of Preventive Medicine and Biostatistics, University of Toronto, 1992-6, special expert in the Division of Cancer Prevention, US National Cancer Institute, 1997, Senior Epidemiologist, International Agency for Research on Cancer 1998-9 and Head, Division of Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, 2000-3. His research encompasses cancer control, prevention and screening.

Dr Rabab Gaafar, NCI, Cairo University

Prof and Head of Medical Oncology Dept & National Representative of ESMO in Egypt and Africa

Prof. Rabab Gaafar received her M.B.B.Ch. from Faculty of Medicine, Cairo University, M. Sc. General Medicine from Faculty of Medicine, Cairo University, and M.D. certification in Medical Oncology from the National Cancer Institute, Cairo University. Prof. Rabab Gaafar is directing the Thoracic Oncology Program at NCI, Cairo and she is also heading the Early Detection Prevention Unit at the Institute since 2006. She is currently chairman of Quality Assurance in the Board of the European Organization for Research and Treatment of Cancer Lung Cancer Group (EORTC). Prof. Rabab Gaafar has published more than 150 publications in National and International Journals and is in the Editorial Board for the journal of the National Cancer Institute, Cairo. In (2007) and (2008), she received an Award for distinguished publications in International peer-reviewed journals. She also had received previously the Medical Syndicate Award of Cairo in 2003 and that of Egypt in 2004. In the year 2009, she received Cairo University Award of appreciation for excellence. Prof. Rabab Gaafar holds memberships in several professional Societies including the International Association for the Study of Lung Cancer (IASLC), European Society of Medical Oncology (ESMO), Mediterranean Oncology Group (MOG), International Network for Cancer Treatment and Research (INCTR), Egyptian Cancer Society and Board member of Arab Medical Association and Egyptian Foundation for research of Cancer and Member of executive committee in European Arab School of Oncology (EASO). As of January 2008, she is now the regional representative for Egypt and North Africa for the European Society of Medical Oncology (ESMO). Recently, she is National representative for Egypt in the Mediterranean Multidisciplinary Oncology Forum (MMOF). Prof. Rabab Gaafar is mainly interested in solid tumors mainly Lung Cancer, Mesothelioma, and Breast Cancer, targeted therapy and new drugs.

Prof. Nada Alwan, Pioneering National Breast Cancer Research & Early Detection Program, Iraq, Executive Director

As a Professor of Pathology, directing the Breast and Cervical Cancer Research Unit (Baghdad University Medical College/MoHESR) and the Main Referral Training Center for Early Detection of Breast Tumours (Medical City Teaching Hospital/MOH), Dr Alwan devoted her scientific efforts and clinical practice to early detection and screening for breast cancer in Iraq. Together with other colleagues and in collaboration with WHO, Dr. Nada Alwan organized the National Program for Early Detection and Down Staging of Breast Cancer in Iraq (MoH, 2001). Since then, specialized centers and clinics for early detection of breast cancer were established all over the 18 Iraqi Governorates. She supervised several national and international training courses focusing on updating knowledge and strengthening skills of the involved professionals. In 2008, under the umbrella of the Common Secretariat for the Council of Ministers and the Iraqi Parliament, Dr. Alwan established the "Pioneering National Breast Cancer Research Program" which is currently chaired by the Ministry of Higher Education and Scientific Research (MoHESR) that coordinates national efforts in collaboration with the concerned ministries; including Ministry of Health (MoH), Ministry of Science & Technology (MoST), Ministry of Labour & Social Affairs (MoLSA), Ministry of Environment (MoE) and local NGOs. As an executive director of that national program, and following a visit to the Screening Group of IARC/Lyon (July 2009), Dr. Alwan developed, with their assistance, a comprehensive breast cancer information system. Currently, plans are designed to use that database model to compare the demographic characteristics, clinicopathological presentations and management outcomes of breast cancer patients within selected countries in the Middle East including Iraq, Jordan, Lebanon and Egypt. Within the field of adopting national cancer control strategies and establishing breast cancer early detection programs, Dr. Alwan served as an international expert and technical advisor to: WHO/EMRO (2007-2009), WHO/IAEA-PACT Technical Cooperation Program (2009-2010), US Middle East Partnership Initiative (MEPI/2007, 2009), Suzan G Komen for the Cure (2009) and the Jordan National Breast Cancer Program (2010).

Dr Amal Samy Ibrahim, National Cancer Institute, Egypt

Professor of Epidemiology and Director of the National Cancer Registry of Egypt

Professor Ibrahim is Professor of Epidemiology and previous vice Dean of community services in the National Cancer Institute- Cairo University. He also acted as visiting professor in the department of Epidemiology, UCLA, US. He graduated from the faculty of medicine in 1962 and got his master degrees in Internal Medicine and Cardiology from Cairo University, and his Doctorate degree in Public health from Paris University in 1971. He has a vast experience teaching Epidemiology and Statistics for doctors and nurses in many Egyptian Universities. This included undergraduate and postgraduate courses and he actually initiated these courses in the Cancer Institute and Cairo University. He is a field epidemiologist. He shared in many national surveys that covered different disciplines related to chronic non-communicable diseases including Cancer, Hypertension, Diabetes and Atherosclerosis. For more than 30 years, he had been deeply involved in cancer registration. He is Director of the National Cancer Registry of Egypt. He is one of the founders of Mediterranean Oncology society (MOS) and Mediterranean Task Force for Cancer Control (MTCC).

Dr Andy Smith, Hologic Inc, USA, Senior Director, Imaging Science.

Dr. Andy Smith is the Senior Director of Imaging Science for Hologic, Inc. He has been involved in medical imaging research and development for over 20 years, with a current focus on advanced breast imaging technologies such as tomosynthesis. He lectures widely around the world on breast imaging and physics, and is a co-author on over 50 patents and patent applications. He received his B.S. and Ph.D. degrees in physics from the Massachusetts Institute of Technology.

Dr Hussein Khaled, Cairo University, Egypt

Prof. of Medical Oncology and Vice President for Postgraduate Studies and Research

Professor of Medical Oncology and the previous Dean of the National Cancer Institute, Cairo University. He is currently the Vice President of Cairo University for Graduate Studies and Research. He has many national and international activities. Professional membership includes : European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Organization for Research and Treatment of Cancer (EORTC) – Lymphoma Group, Egyptian Foundation for Cancer Research (Secretary General), INCTR (President of Egyptian Branch), Egyptian Cancer Society, NIH Alumni Association (Secretary General of Egyptian Chapter), President of South and East Mediterranean College of Oncology, Egyptian Academy of Science (Health Sector), Specialized National Council (Health Sector). He is Editor-in-Chief of the journal of advanced research of Cairo University and he is a member of the Editorial Board of the Annuals of Oncology since 3 years. He is also the Head of the Scientific Council of the East Mediterranean region non-governmental alliance against cancer. His scientific contribution includes more than 110 papers, and 60 abstracts in both national and international journals, and conferences. The main research interest is in the Clinico-biologic characteristics and management of Bilharzial related bladder cancer, non-Hodgkin's lymphomas, and breast cancer. He is the editor on a book on lymphomas, Nutrition and Cancer (in Arabic), and associate editor on a book on Breast Cancer. In addition to the latest international data and information, these books include as well all relevant local Egyptian experience and results of management of these important oncologic problems.

Dr. Sayed A Marei, Cairo University, Egypt

Professor of General Surgery and Head of the Breast Surgery Clinic

Dr. Sayed A Marei is a Professor of General Surgery Kasr El Aini Medical school Cairo University. He obtained his M.D degree in Gen Surgery in 1985. He is currently the head of the surgical breast clinic in the general surgery department Kasr El Aini Medical school. His previous main interest has been surgery for GI malignancies. His main current interest for the last few years has been the initiation and maintenance of a multidisciplinary breast clinic, as well as the supervision of research in the domain of surgery of breast cancer and oncoplastic techniques. The clinic has been offering its free surgical service which includes breast reconstruction for breast cancer patients

Prof Dr Alaa Kandil, Alexandria School of Medicine, Egypt

Professor of Clinical Oncology

Alaa Kandil has started his oncology profession 1982 where he was appointed as a full time resident in the department of Clinical Oncology & Nuclear medicine after which he obtained his Master degree (general Grade, Excellent). His training included dealing with all types of malignancies with radiation and medical oncology programs. Shortly after, he had a 3 months training at ST Luke's, Hospital, Guilford and the Royal Marsden Hospital, London, England. 1989, Dr kandil went to Stanford university, California, USA where had all the work of his Doctorate degree thesis done and his thesis (drug resistance, interaction between chemotherapy & hyperthermia) was defended back home in 1991 and he passed his exams to obtain his Doctorate degree and been appointed as a lecturer in his University. 1993, Dr Kandil joined the Department of Oncology at the King Faisal Specialist Hospital (Tertiary Care Center), Riyadh, Saudi Arabia for 8.5 years. Dr Kandil is full professor at the department of Clinical Oncology & Nuclear Medicine, Alexandria School of Medicine (2003 till present). Dr Kandil has over 30 publications in international journals and a great deal of experience in managing malignancies of the breast, head & neck, lymphomas and gynecological malignancies

Dr Carlo V. Catapano, Institute of Southern Switzerland, Switzerland

Director, Lab of Experimental Oncology

Carlo V. Catapano, MD, PhD, Director, Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (IOSI), received the MD degree in 1983 from the University of Naples, Italy. From 1983 to 1988 he was a resident in the Medical Oncology Division at the University of Naples and a fellow in Cancer Pharmacology at the "Mario Negri" Institute for Pharmacological Research in Milan, Italy. From 1988 to 1993 he worked in the Wake Forest University Comprehensive Cancer Center in Winston-Salem, NC, USA, where he received the PhD in Biochemistry. In 1993 he moved to the Medical University of South Carolina (MUSC) in Charleston, SC, USA, where he held faculty appointments in the Departments of Experimental Oncology, Biochemistry and Molecular Biology, and Medicine/Division of Hematology/Oncology. He was senior investigator at the Hollings Cancer Center, the Center for Molecular and Structural Biology, and the Laboratory of Cancer Genomic of the MUSC. Since 2003 he is the Director of the research laboratories of the IOSI in Bellinzona, Switzerland. His research interests are in the field of experimental therapeutics, molecular pharmacology, development of molecular- and gene-targeted therapeutics, transcription factors and epigenetic mechanisms along with translational and clinical studies on new anticancer agents.



Dr Omalkhair Abulkhair, King Abdul Aziz Medical city, KSA
Section Head & Consultant, Dept of Oncology

Dr. Omalkhair Abulkhair is currently the Section Head of the Division of Adult Medical Oncology, Department of Oncology in King Abdulaziz Medical City – Riyadh, Kingdom of Saudi Arabia and Assistant Professor in King Saud bin Abdulaziz University for Health Sciences. Being one of the renowned oncologists in the Middle East, she was nominated to be part of the Women in High Places: Fight against Cancer, an international organization of prominent women in their respective areas. She is the Course Director of major symposia and conferences in the department such as the Best of CTSC-AACR San Antonio Breast Cancer Symposium and Cancer Prevention and Early Detection Symposium. She was also selected as the Chairman for MENA-NCCN Guidelines Committee for Breast Cancer. This committee aims to unify the guidelines for breast cancer management in the region. Furthermore, Dr. Abulkhair was also chosen to lead the National Committee for Breast Cancer by the Ministry of Health in Riyadh.

Dr Hatem Azim, Jules Bordet Institute, Belgium, Research fellow

Dr. Hatem A. Azim, Jr is a medical oncologist who completed his oncology training in the National Cancer Institute in Cairo in 2007. Afterwards, he served as a fellows for brief periods in the European Institute of Oncology in Milan and Bl Deaconess teaching hospital, Harvard University in Boston. He holds two Masters Degrees in oncology from the University of Newcastle Upon Tyne and Cairo University. Since September 2009, he serves as a research fellow in Jules Bordet Institute and undergoing a PhD program at the Universite Libre De Bruxelles in Brussels. His current work is mainly focused in the field of clinical and translational breast cancer research under the mentorship of world renowned experts Prof. Martine Piccart & Christos Sotiriou. His main areas of expertise is in the field of breast cancer and pregnancy particularly managing breast cancer during pregnancy and the long term effects of pregnancy and breastfeeding on patients with history of breast cancer. He is currently developing a PhD project on gene expression profiling of breast cancers diagnosed during pregnancy. Dr. Azim published around 30 peer-reviewed articles mainly in the field of breast cancer and pregnancy associated tumors.

Dr. Heba Sweed, Global Initiative for Breast Cancer Awareness, Egypt
Country Program Manager

Dr. Heba Sweed is the Program Manager of the Global Initiative for Breast Cancer Awareness in Egypt. She is a qualified physician with 10 years experience in the medical field, including a managerial position in a multinational pharmaceutical company developing and managing patients and healthcare providers' educational programs. She most recently held the position of Quality Improvement Specialist for a project focusing on integrated maternal and child health at all levels. As part of her MBA, Dr. Sweed focused her thesis on exploring and identifying the needs of communities in rural areas, and building the capacity of small NGOs to develop, manage and promote micro-health insurance schemes for these communities based on their needs

Dr Norran H. Said, Cairo University, Egypt
Breast Radiologist, Egyptian Society of Women's Imaging & Health Care, Treasurer

Dr Norran H Said is a dedicated breast imaging radiologist at Cairo University Hospital, and Cairo Radiology Center (Cairo Scan). She is also an active breast screening radiologist at the Egyptian National Breast screening Program, known as the Women's Health Outreach Program. More over, she is a founding member and treasurer of the Egyptian Society of Women's Imaging & Health Care, as well as the National Foundation for Breast Cancer Elimination. Her main field of interest & research is Breast MRI.

Dr Ashraf Selim, Cairo University, Egypt, Head Of Women's Imaging Unit,
Consultant of Egyptian National Breast Screening Program & President of **Egyptian Society of Women's Imaging & Health Care (ESWIH)**

Dr Ashraf Selim is a professor of radiology at Cairo University, and head of the women's imaging unit. Moreover, he is a consultant at the Egyptian National Breast screening program, and Executive Manager of Cairo Scan, the largest radiological private center in Egypt. As an enthusiast on breast imaging, he was one of the first to implement it and has presented & published several related studies. In 2005, he became the President & founder of the Egyptian Society of Women's Imaging & Health Care, which organizes annual workshops to upgrade radiologists breast screening skills, as well as women's health seminars

Dr Aly Abdel Razek, Gulf International Cancer Center, UAE, Executive Director

Dr. Abdel Razek graduated from Cairo University. He completed his residency in 1976 at Washington University in St. Louis, Mo., USA. He is board certified in both Radiation Oncology and Pediatrics. He co-authored four text books in radiation oncology and contributed to many publications in oncology journals. He served on the national committee of the Southwest Oncology Group, Intergroup Ewings Sarcoma and National Wilms Tumor Committee. Dr. Abdel Razek is a Fellow of American College of Radiation Oncology. He is president of Medical Resources International and Chairman and Executive Director of the Gulf International Cancer Center


Dr Raghib Ali, INDOX Cancer Research Network, UK, Director

Dr Raghib Ali is the Director of the INDOX Cancer Research Network, India's largest academic oncology network, which he has led since its establishment in 2005 and a Clinical Epidemiologist at the Cancer Epidemiology Unit at the University of Oxford. He is also an Honorary Lecturer in Clinical Pharmacology, an Honorary Consultant in Acute Medicine at the John Radcliffe Hospital in Oxford and the Richard Doll Medical Tutorial Fellow at Green-Templeton College. His main research interests are the aetiology, prevention & treatment of cancer in South Asian and Middle Eastern populations. He graduated from Cambridge University in 1999 with a distinction in Medicine and was awarded the John Addenbrookes prize for Medicine for the best performance throughout medical school

Meet Our Sponsors

Hologic. Preserving the Gifts of Wellness and Life.

At Hologic our focus is womens' health. Our mission is to Provide Leading Edge Technologies Targeting Womens' Health with an Emphasis on the Early Detection of Diseases – Ultimately Saving Lives. Our passion can be seen in our innovative diagnostic imaging systems for the early detection of breast cancer and osteoporosis assessment, in addition to our innovative and effective technologies in early detection of cancer cervix and treatment of menorrhagia. We strive to continually push the boundaries of imaging to provide you with superior image quality and diagnostic accuracy. Every year, Hologic spends tens of millions of dollars in research and development to advance the field of womens' healthcare. As our clinical areas expand, we are taking on a broader range of health issues, yet our goal remains the same: to deliver innovative technologies that result in better outcomes for women. Working together we cannot fail



MENA Oncology Conference

22nd - 23rd October 2010, Cairo, Egypt

Sales Contract

▶ Conference Code: DB LS 03

Please complete this form and fax back to

+91 804 050 9933

or email to: **judef@fleminggulf.com**

Payment Method

Please debit my

Visa Eurocard/Mastercard Amex Diners club

Card Billing Address:

Street: _____

City: _____

Post/Zip Code

Card Holder's name: _____

Card Holder's Signature: _____

Card Number: _____

Visa CVC Number or Eurocard/Mastercard CVW Number

(last 3 digits on the back on the card) _____

Valid from _____ / _____ Expiry Date _____ / _____

I agree to Fleming Gulf terms and Conditions and Fleming Gulf debiting my card.

Registration Details

Please write in CAPITAL LETTERS

Ms Mrs Mr Surname: _____

Name: _____

Job Title: _____

Email: _____

Ms Mrs Mr Surname: _____

Name: _____

Job Title: _____

Email: _____

Ms Mrs Mr Surname: _____

Name: _____

Job Title: _____

Email: _____

Organisation: _____

Contact person: _____

Email: _____

City: _____

Country: _____

Phone: _____

Fax: _____

Address: _____

Nature of business: _____

Website: _____

Authorization

Signatory must be authorized on behalf of contracting organisation

Name: _____

Date: _____

Signature: _____

Booking is invalid without a signature

Fleming Gulf

Standard price

\$ 500
per delegate

Discounted price

\$ 300
per delegate

Payment is required within 5 working days
19 USD administration charge will be applied

Terms and Conditions:

Fleming Gulf requires the full payment within 5 days from receipt of invoice. Fleming Gulf reserves the right to refuse entry to any customer who has not paid their invoice. A credit card guarantee may be requested if full payment has not been received. All bookings carry a 50% liability after the booking has been made. There will be no refunds for cancellations received on or after one month before the start of the conference. If you decide to cancel after this date the full invoice remains payable.

Fleming Gulf reserves the right to change the content, timing, speakers or venue should circumstances require. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of Fleming Gulf. If such a situation arises we will endeavour to reschedule the event. However, Fleming Gulf cannot be held responsible for any cost, damage or expenses which may be incurred by the customer as a consequence of the event being postponed or cancelled. Fee does not include travel, hotel accommodation, transfers or insurance.

Fee includes:

- ▶ Documentation Pack
- ▶ Course Sessions
- ▶ Lunches and refreshments

Hotel Accommodation:

Overnight accommodation is not included in the registration fee. A reduced rate will be available at the Conference Hotel. Booking form will be sent out right after the venue will be confirmed, but not later than one month prior to the event.